Cargando…

Metabolic Syndrome and Risk of Gastrointestinal Cancers: An Investigation Using Large-scale Molecular Data

BACKGROUND & AIMS: Gastrointestinal cancer risk is influenced by the presence of metabolic syndrome (MetS). However, previous epidemiologic studies lacked full serological biomarker data for the classification of MetS, and the interaction of MetS with germline cancer risk variants is unknown. ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Rothwell, Joseph A., Jenab, Mazda, Karimi, Mojgan, Truong, Thérèse, Mahamat-Saleh, Yahya, Ferrari, Pietro, Dashti, S. Ghazaleh, Kühn, Tilman, Cross, Amanda J., Severi, Gianluca, Gunter, Marc J., Murphy, Neil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: W.B. Saunders for the American Gastroenterological Association 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9117007/
https://www.ncbi.nlm.nih.gov/pubmed/34687971
http://dx.doi.org/10.1016/j.cgh.2021.10.016
_version_ 1784710235332542464
author Rothwell, Joseph A.
Jenab, Mazda
Karimi, Mojgan
Truong, Thérèse
Mahamat-Saleh, Yahya
Ferrari, Pietro
Dashti, S. Ghazaleh
Kühn, Tilman
Cross, Amanda J.
Severi, Gianluca
Gunter, Marc J.
Murphy, Neil
author_facet Rothwell, Joseph A.
Jenab, Mazda
Karimi, Mojgan
Truong, Thérèse
Mahamat-Saleh, Yahya
Ferrari, Pietro
Dashti, S. Ghazaleh
Kühn, Tilman
Cross, Amanda J.
Severi, Gianluca
Gunter, Marc J.
Murphy, Neil
author_sort Rothwell, Joseph A.
collection PubMed
description BACKGROUND & AIMS: Gastrointestinal cancer risk is influenced by the presence of metabolic syndrome (MetS). However, previous epidemiologic studies lacked full serological biomarker data for the classification of MetS, and the interaction of MetS with germline cancer risk variants is unknown. METHODS: We investigated the associations between MetS and gastrointestinal cancer risk (overall, colorectal, pancreatic, esophageal adenocarcinoma, esophageal squamous cell carcinoma, stomach cardia, stomach non-cardia, hepatocellular carcinoma, and intrahepatic bile duct cancer) in 366,016 United Kingdom Biobank participants with comprehensive serum biomarker and genotype data. MetS status was determined by 3 different definitions at baseline, and, in 15,152 participants, at a repeat assessment after a median of 4.3 years of follow-up. Multivariable hazard ratios and 95% confidence intervals for cancer outcomes were estimated using Cox proportional hazards models. Analyses stratified by polygenic risk score were conducted for colorectal and pancreatic cancers. RESULTS: During a median follow-up of 7.1 years, 4238 incident cases of a gastrointestinal cancer occurred. MetS at baseline was associated with higher risk of overall gastrointestinal cancer by any definition (hazard ratio, 1.21; 95% confidence interval, 1.13–1.29, harmonized definition). MetS was associated with increased risks of colorectal cancer, colon cancer, rectal cancer, hepatocellular carcinoma, pancreatic cancer in women, and esophageal adenocarcinoma in men. Associations for colorectal cancer and pancreatic cancer did not differ by polygenic risk score strata (P-heterogeneity 0.70 and 0.69, respectively), and 80% of participants with MetS at baseline retained this status at the repeat assessment. CONCLUSIONS: These findings underscore the importance of maintaining good metabolic health in reducing the burden of gastrointestinal cancers, irrespective of genetic predisposition.
format Online
Article
Text
id pubmed-9117007
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher W.B. Saunders for the American Gastroenterological Association
record_format MEDLINE/PubMed
spelling pubmed-91170072022-06-14 Metabolic Syndrome and Risk of Gastrointestinal Cancers: An Investigation Using Large-scale Molecular Data Rothwell, Joseph A. Jenab, Mazda Karimi, Mojgan Truong, Thérèse Mahamat-Saleh, Yahya Ferrari, Pietro Dashti, S. Ghazaleh Kühn, Tilman Cross, Amanda J. Severi, Gianluca Gunter, Marc J. Murphy, Neil Clin Gastroenterol Hepatol Original Article BACKGROUND & AIMS: Gastrointestinal cancer risk is influenced by the presence of metabolic syndrome (MetS). However, previous epidemiologic studies lacked full serological biomarker data for the classification of MetS, and the interaction of MetS with germline cancer risk variants is unknown. METHODS: We investigated the associations between MetS and gastrointestinal cancer risk (overall, colorectal, pancreatic, esophageal adenocarcinoma, esophageal squamous cell carcinoma, stomach cardia, stomach non-cardia, hepatocellular carcinoma, and intrahepatic bile duct cancer) in 366,016 United Kingdom Biobank participants with comprehensive serum biomarker and genotype data. MetS status was determined by 3 different definitions at baseline, and, in 15,152 participants, at a repeat assessment after a median of 4.3 years of follow-up. Multivariable hazard ratios and 95% confidence intervals for cancer outcomes were estimated using Cox proportional hazards models. Analyses stratified by polygenic risk score were conducted for colorectal and pancreatic cancers. RESULTS: During a median follow-up of 7.1 years, 4238 incident cases of a gastrointestinal cancer occurred. MetS at baseline was associated with higher risk of overall gastrointestinal cancer by any definition (hazard ratio, 1.21; 95% confidence interval, 1.13–1.29, harmonized definition). MetS was associated with increased risks of colorectal cancer, colon cancer, rectal cancer, hepatocellular carcinoma, pancreatic cancer in women, and esophageal adenocarcinoma in men. Associations for colorectal cancer and pancreatic cancer did not differ by polygenic risk score strata (P-heterogeneity 0.70 and 0.69, respectively), and 80% of participants with MetS at baseline retained this status at the repeat assessment. CONCLUSIONS: These findings underscore the importance of maintaining good metabolic health in reducing the burden of gastrointestinal cancers, irrespective of genetic predisposition. W.B. Saunders for the American Gastroenterological Association 2022-06 /pmc/articles/PMC9117007/ /pubmed/34687971 http://dx.doi.org/10.1016/j.cgh.2021.10.016 Text en © 2022 by the AGA Institute. Published by Elsevier Inc. https://creativecommons.org/licenses/by/3.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Original Article
Rothwell, Joseph A.
Jenab, Mazda
Karimi, Mojgan
Truong, Thérèse
Mahamat-Saleh, Yahya
Ferrari, Pietro
Dashti, S. Ghazaleh
Kühn, Tilman
Cross, Amanda J.
Severi, Gianluca
Gunter, Marc J.
Murphy, Neil
Metabolic Syndrome and Risk of Gastrointestinal Cancers: An Investigation Using Large-scale Molecular Data
title Metabolic Syndrome and Risk of Gastrointestinal Cancers: An Investigation Using Large-scale Molecular Data
title_full Metabolic Syndrome and Risk of Gastrointestinal Cancers: An Investigation Using Large-scale Molecular Data
title_fullStr Metabolic Syndrome and Risk of Gastrointestinal Cancers: An Investigation Using Large-scale Molecular Data
title_full_unstemmed Metabolic Syndrome and Risk of Gastrointestinal Cancers: An Investigation Using Large-scale Molecular Data
title_short Metabolic Syndrome and Risk of Gastrointestinal Cancers: An Investigation Using Large-scale Molecular Data
title_sort metabolic syndrome and risk of gastrointestinal cancers: an investigation using large-scale molecular data
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9117007/
https://www.ncbi.nlm.nih.gov/pubmed/34687971
http://dx.doi.org/10.1016/j.cgh.2021.10.016
work_keys_str_mv AT rothwelljosepha metabolicsyndromeandriskofgastrointestinalcancersaninvestigationusinglargescalemoleculardata
AT jenabmazda metabolicsyndromeandriskofgastrointestinalcancersaninvestigationusinglargescalemoleculardata
AT karimimojgan metabolicsyndromeandriskofgastrointestinalcancersaninvestigationusinglargescalemoleculardata
AT truongtherese metabolicsyndromeandriskofgastrointestinalcancersaninvestigationusinglargescalemoleculardata
AT mahamatsalehyahya metabolicsyndromeandriskofgastrointestinalcancersaninvestigationusinglargescalemoleculardata
AT ferraripietro metabolicsyndromeandriskofgastrointestinalcancersaninvestigationusinglargescalemoleculardata
AT dashtisghazaleh metabolicsyndromeandriskofgastrointestinalcancersaninvestigationusinglargescalemoleculardata
AT kuhntilman metabolicsyndromeandriskofgastrointestinalcancersaninvestigationusinglargescalemoleculardata
AT crossamandaj metabolicsyndromeandriskofgastrointestinalcancersaninvestigationusinglargescalemoleculardata
AT severigianluca metabolicsyndromeandriskofgastrointestinalcancersaninvestigationusinglargescalemoleculardata
AT guntermarcj metabolicsyndromeandriskofgastrointestinalcancersaninvestigationusinglargescalemoleculardata
AT murphyneil metabolicsyndromeandriskofgastrointestinalcancersaninvestigationusinglargescalemoleculardata